Clinical Trials › NCT06782490
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Sponsored by Celgene
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 200
Target enrollment
11
U.S. states
Jun 2025
Start date
Jun 2027
Expected completion
Interventions / Treatments
BMS-986368Placebo
Conditions studied
Multiple Sclerosis Spasticity
Where this trial is running (14 sites)
Ohio3 sites
Cincinnati · Columbus · Columbus
Florida2 sites
Naples · Tampa
Alabama1 site
Birmingham
Arizona1 site
Scottsdale
Colorado1 site
Aurora
Kansas1 site
Kansas City
Massachusetts1 site
Foxborough
Missouri1 site
St Louis
Pennsylvania1 site
Philadelphia
Tennessee1 site
Knoxville
Washington1 site
Kirkland
Participating MS centers on MS Buddy (6)
John L. Trotter Multiple Sclerosis Center
Saint Louis, MO
Saint Louis, MO
Neurology Center of New England, P.C.
Foxboro, MA
Foxboro, MA
Hope Neurology, PLLC
Knoxville, TN
Knoxville, TN
USF Multiple Sclerosis Center
Tampa, FL
Tampa, FL
The Waddell Center for Multiple Sclerosis
Cincinnati, OH
Cincinnati, OH
EvergreenHealth Multiple Sclerosis Center
Kirkland, WA
Kirkland, WA
MS centers in Ohio
Compare treatment centers near a trial site by center type, providers and trials.
View Ohio centersMore Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.